Carbamazepine in mixed frontal lobe and psychiatric disorders.
Carbamazepine was given to five patients with mixed frontal lobe disease and a variety of primary psychiatric disorders. All five patients benefited significantly. A decrease in affective lability was the most consistent result. Carbamazepine may be an alternative to chronic high-dose neuroleptic therapy in these patients.
D000368:Aged; D001927:Brain Diseases / Q000150:complications* / Q000188:drug therapy / Q000523:psychology; D002220:Carbamazepine / Q000627:therapeutic use*; D005625:Frontal Lobe; D006801:Humans; D008297:Male; D001523:Mental Disorders / Q000150:complications* / Q000188:drug therapy / Q000523:psychology; D008875:Middle Aged; D019965:Neurocognitive Disorders / Q000150:complications / Q000188:drug therapy / Q000523:psychology; D011618:Psychotic Disorders / Q000150:complications / Q000188:drug therapy / Q000523:psychology; D012559:Schizophrenia / Q000150:complications / Q000188:drug therapy
D002220:Carbamazepine